Background {#Sec1}
==========

Acute kidney injury (AKI), a common complication after cardiac surgery, occurs in one out of three patients \[[@CR1]--[@CR3]\]. While it has been previously thought that AKI resolves with no long-term sequelae, it is now increasingly recognized that it is associated with development of chronic kidney disease (CKD), end-stage renal disease (ESRD) and increases long-term mortality \[[@CR4]--[@CR9]\].

Amongst cardiac surgical patients, Rydén et al. demonstrated that a small increase in serum creatinine was associated with an almost 3-fold increase in the long-term risk of developing ESRD \[[@CR10]\]; while Lo LJ et al. found that amongst all hospitalized patients, dialysis-requiring AKI patients had a 28-fold increased risk of developing stage 4 chronic kidney disease or ESRD, compared with patients who did not develop AKI \[[@CR11]\].

This association between an episode of AKI after cardiac surgery and the risk of subsequent development of ESRD in an Asian population is unknown. It is therefore important to track the trajectory of progression of kidney disease following an acute episode of AKI in our Asian population, especially as the health and financial burden of ESRD is likely increased with our high prevalence of diabetes and younger age of presentation for cardiac surgery. Furthermore, given the extremely high local burden of ESRD \[[@CR12]\], we embarked on this study to determine the long-term risk of ESRD and mortality in Singapore post-AKI after cardiac surgery.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

With Institutional Review Board approval (Domain Specific Review Board 2015/00398) and written informed consent, we prospectively followed up all adult patients above 21 years old from August 2008 till 30 December 2014. These patients underwent cardiac surgery at two main heart centres in Singapore between August 2008 and July 2012. Perioperative safety and outcomes data were prospectively collected and entered into a cardiac anaesthesia database. The exclusion criteria for analysis were: (1) non-citizens and non-permanent residents; (2) patients on existing dialysis; (3) pre-existing ESRD patients; and (4) inpatient mortality cases.

Definition of eGFR, normal serum creatinine, AKI, ESRD {#Sec4}
------------------------------------------------------

The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation \[[@CR13]\].

Normal serum creatinine was defined as 60 to 105 μmol/L for males and 40 to 75 μmol/L for females.

AKI was defined using the Acute Kidney Injury Network (AKIN) criteria - stage 1: ≥26.4 μmol/L or ≥50--100%; stage 2: 100--200%; stage 3: ≥354 μmol/L with an acute increase of ≥44 μmol/L or ≥200% increase between pre- and post-operative serum creatinine. The pre-operative serum creatinine was defined as the creatinine value recorded within 1 week before surgery unless there was a material change in the patient's condition; while the peak post-operative serum creatinine was the highest creatinine within 48 h after surgery \[[@CR6]\].

ESRD was defined as stage 5 CKD (where the glomerular filtration rate was \<15 ml/min/1.73 m^2^) requiring renal replacement therapy \[[@CR14]\].

Outcome data {#Sec5}
------------

All Singaporean citizens and permanent residents have a unique personal identification number. Identification of ESRD patients amongst the cohort was accomplished through record linkage of cohort files with the Singapore Renal Registry of the National Registry of Diseases Office. This is a nationwide database of patients who have received renal replacement therapy and includes the date of entry into a renal replacement program and/or renal transplantation. The data capture for ESRD is estimated to be 95% complete \[[@CR15]\]. This study used the date of first renal replacement therapy to define the start of ESRD as reported to the Registry.

Survival records were captured through matching of patient's identification number with the Singapore Registry of Births and Deaths.

Statistical analysis {#Sec6}
--------------------

Population demographics, medical history, pre-operative risk assessment, intra-operative variables and post-operative outcomes were analysed descriptively. Univariate analyses were done using 2-tailed unpaired *T*-test for continuous variables and Chi-square for categorical variables to identify the risk factors for ESRD. Patients contributed person-time in days from the time of surgery and were censored at the time of death from any cause, start of renal replacement therapy or end of the follow up period (December 30, 2014), whichever is earlier. The Cox proportional hazards regression model was used to analyse associations between AKI and the primary outcome of ESRD and the secondary outcome of death. The statistical significance of variables was taken as *p* \< 0.05. All statistical analyses were performed using IBM SPSS version 22.0 (Armonk, NY, USA).

Results {#Sec7}
=======

The patient characteristics are shown in Table [1](#Tab1){ref-type="table"}. A total of 3008 patients were recruited during the study period. The total number of patients who met the inclusion and exclusion criteria was 2666. The mean age was 59.3 ± 10.5 years of which 523 were women.Table 1Univariate analysis of perioperative factors and acute kidney injury for the whole cohortVariablesWhole cohort (*n* = 2666)No AKI (*n* = 1889)AKIN 1 (*n* = 608)AKIN 2 and 3 (*n* = 169)*p*-valuePre-operative Age (years)59.3 ± 10.558.0 ± 10.562.3 ± 9.662.4 ± 10.6\<0.001 Gender: male2143 (80.4)1534 (81.2)486 (79.9)123 (72.8)0.029 EthnicityChinese1912 (71.7)1390 (73.6)414 (68.1)108 (63.9)\<0.001Malay425 (15.9)271 (14.3)126 (20.7)28 (16.6)Indian329 (12.3)228 (12.1)68 (11.2)33 (19.5) Body mass index (kg/m^2^)25.0 ± 4.124.9 ± 4.025.4 ± 4.324.9 ± 4.70.032 Diabetes mellitus1205 (45.2)793 (42.0)294 (48.4)118 (69.8)\<0.001 Hypertension1998 (74.9)1348 (71.4)503 (82.7)147 (87)\<0.001 Myocardial infarction1559 (58.5)1072 (56.7)379 (62.3)108 (63.9)0.017 Congestive cardiac failure435 (16.3)260 (13.8)130 (21.4)45 (26.6)\<0.001 Renal impairment225 (8.4)90 (4.8)99 (16.3)36 (21.3)\<0.001 Beta-blocker1998 (74.9)1377 (73.1)482 (79.3)139 (82.2)0.001 ACE-inhibitor1300 (48.8)905 (48.0)306 (50.3)89 (52.7)0.365 Calcium channel blocker521 (19.5)331 (17.6)144 (23.7)46 (27.2)\<0.001 Statin2159 (81.0)1526 (81.0)494 (81.7)139 (82.2)0.881 Diuretic480 (18.0)276 (14.6)149 (24.5)55 (32.5)\<0.001 Ejection fraction (\<30%)185 (6.9)110 (5.9)58 (9.6)17 (10.2)0.002 Pre-operative creatinine (μmol/L)91.0 ± 42.785.7 ± 34.6103.5 ± 51.598.7 ± 35.5\<0.001 Pre-operative eGFR (ml/min/1.73 m^2^)81.0 ± 21.684.8 ± 19.371.9 ± 23.971.7 ± 23.9\<0.001 Pre-operative haemoglobin (g/dL)13.5 ± 1.713.8 ± 1.613.1 ± 1.812.7 ± 1.8\<0.001 EuroSCORE logistic3.6 ± 4.63.1 ± 3.74.8 ± 6.04.9 ± 6.2\<0.001Surgical variables Coronary artery bypass graft surgery2191 (82.2)1546 (82.2)506 (83.4)139 (82.2)0.802 Valvular surgery622 (23.3)433 (22.9)148 (24.3)41 (24.3)0.733 Cardiopulmonary bypass2578 (96.7)1820 (96.3)595 (97.9)163 (96.4)0.188 IABP249 (9.3)130 (6.9)89 (14.7)30 (17.9)\<0.001 Cardiopulmonary bypass time (min)113.5 ± 49.0107.0 ± 43.4125.7 ± 56.2137.3 ± 64.7\<0.001 Aortic cross clamp time (min)67.2 ± 36.463.5 ± 32.874.1 ± 42.579.5 ± 46.0\<0.001 Inotrope use1652 (62.0)1120 (59.9)409 (67.7)123 (72.8)\<0.001Haemodilution Prebypass haematocrit (%)37.8 ± 4.938.3 ± 4.636.9 ± 5.335.8 ± 4.8\<0.001 Lowest haematocrit during bypass (%)24.4 ± 3.924.9 ± 3.923.4 ± 3.722.3 ± 3.8\<0.001 RBC transfusion746 (28.0)426 (22.6)238 (39.1)82 (48.5)\<0.001Intensive care unit variables Inotrope use1228 (46.1)780 (41.3)336 (55.4)112 (66.3)\<0.001 New need for dialysis59 (2.2)12 (0.6)21 (3.5)26 (15.4)\<0.001 Lowest haemoglobin in 1st 24 h (g/dL)9.7 ± 1.69.9 ± 1.59.2 ± 1.48.8 ± 1.4\<0.001 RBC transfusion1010 (37.9)608 (32.2)303 (49.9)99 (58.6)\<0.001 Total length of hospitalization (days)11.0 ± 10.69.2 ± 5.613.2 ± 9.622.0 ± 30.2\<0.001Outcomes End-stage renal disease24 (0.9)6 (0.3)12 (2.0)6 (3.6)\<0.001 5-year mortality128 (4.8)68 (3.6)41 (6.7)19 (11.2)\<0.001Data represent number (percent) or mean ± standard deviation*AKI* Acute Kidney Injury, *AKIN* Acute Kidney Injury Network, *EuroSCORE* European System for Cardiac Operative Risk Evaluation, *eGFR* estimated glomerular filtration rate, *IABP* intra-aortic balloon pump, *RBC* red blood cell

Overall incidence of AKI and ESRD {#Sec8}
---------------------------------

The overall incidence of post-operative AKI in our cohort was 29.1% (*n* = 777 out of 2666). Of these AKI patients, 78% (*n* = 608), 17.5% (*n* = 134), and 4.5% (*n* = 35) developed AKI of AKIN stage 1, 2 and 3 respectively.

72.7% (*n* = 1938 out of 2666) of patients had normal pre-operative serum creatinine. The mean pre-operative eGFR for the cohort was 81.0 ± 21.6 mL/min/1.73 m^2^. Patients who developed AKI were males, older, had diabetes mellitus and hypertension, and pre-operative anaemia, poorer pre-operative renal function and lower nadir haematocrit during bypass. A total of 59 (2.2%) patients had a new need for dialysis in the post-operative period (Table [1](#Tab1){ref-type="table"}).

During a mean follow-up of 4.4 ± 2.8 years, a total of 24 patients (0.9%) developed ESRD, including 12 (out of 608, 2.0%) with AKIN stage 1 AKI, 5 (out of 134, 3.7%) with AKIN stage 2 AKI, and 1 (out of 35, 2.9%) with AKIN stage 3 AKI. 6 patients (out of 1889, 0.3%) without AKI developed ESRD within the follow-up period. Overall, patients who developed AKI had a 7.4 times (95% Confidence Interval \[C.I.\] 2.943--18.822) significant higher risk of developing ESRD (*p* \< 0.001), compared with patients who did not develop AKI.

The mean age of patients at the diagnosis of ESRD was 57.3 ± 9.4 years. 87.5% of the ESRD patients were males. Patients who developed ESRD had a poorer pre-operative renal function, lower pre-operative haemoglobin and lower nadir haematocrit during bypass, than those who did not develop ESRD (Table [2](#Tab2){ref-type="table"}).Table 2Univariate analysis of perioperative factors and end-stage renal disease for the whole cohortVariablesESRD (*n* = 24)No ESRD (*n* = 2642)*p*-valuePre-operative Age (years)57.3 ± 9.459.3 ± 10.50.604 Gender: male21 (87.5)2122 (80.3)0.345 EthnicityChinese14 (58.3)1898 (71.8)0.304Malay5 (20.8)420 (15.9)Indian5 (20.8)324 (12.3) Body mass index (kg/m^2^)25.2 ± 5.125.0 ± 4.10.839 Diabetes mellitus23 (95.8)1182 (44.7)\<0.001 Hypertension22 (91.7)1976 (74.8)0.058 Myocardial infarction18 (75.0)1541 (58.3)0.099 Congestive cardiac failure8 (33.3)427 (16.2)0.045 Renal impairment15 (62.5)210 (7.9)\<0.001 Beta-blocker21 (87.5)1977 (75.0)0.158 ACE-inhibitor12 (50)1288 (48.8)0.910 Calcium channel blocker10 (41.7)511 (19.4)0.016 Statin24 (100.0)2135 (81.1)0.014 Diuretic8 (33.3)472 (17.9)0.061 Ejection fraction (\<30%)22 (91.7)2440 (93.0)0.683 Pre-operative creatinine (μmol/L)235 ± 12789 ± 36\<0.001 Pre-operative eGFR (ml/min/1.73 m^2^)36.3 ± 25.181.4 ± 21.1\<0.001 Pre-operative haemoglobin (g/dL)11.2 ± 1.713.6 ± 1.7\<0.001 EuroSCORE logistic6.9 ± 9.03.5 ± 4.50.086Surgical variables IABP4 (16.7)245 (9.3)0.276 Cardiopulmonary bypass time (min)103 ± 43113 ± 490.325 Aortic cross clamp time (min)61 ± 2567 ± 370.424 Inotrope use21 (87.5)1631 (62.3)0.011Hemodilution Prebypass haematocrit (%)31.5 ± 4.937.9 ± 4.8\<0.001 Lowest hematocrit during bypass (%)21.5 ± 3.124.4 ± 4.0\<0.001 RBC transfusion13 (54.2)733 (27.7)0.004Intensive care variables Inotrope use13 (54.2)1215 (46.0)0.426 New need for dialysis5 (20.8)54 (2.0)\<0.001 Lowest haemoglobin in 1st 24 h (g/dL)8.4 ± 1.49.7 ± 1.6\<0.001 RBC transfusion15 (62.5)995 (37.7)0.013 Total length of hospitalization (days)14.7 ± 10.510.9 ± 10.60.083Outcomes Acute kidney injury18 (75.0)759 (28.7)\<0.001 5-year mortality6 (25.0)122 (4.6)0.001Data represent number (percent) or mean ± standard deviation*ESRD* end-stage renal disease, *EuroSCORE* European System for Cardiac Operative Risk Evaluation, *eGFR* estimated glomerular filtration rate, *IABP* intra-aortic balloon pump, *RBC* red blood cell

The incidence of ESRD increased with advancing AKIN stage (Fig. [1](#Fig1){ref-type="fig"}). Compared with the non-AKI patients, the risk of developing ESRD was 6 and 11 times higher for patients who developed AKI of AKIN stage 1, and stage 2 and 3 respectively (*p* \< 0.001, *p* \< 0.001) (Table [2](#Tab2){ref-type="table"}). After multivariate Cox regression analysis, the hazard ratio (HR) for developing ESRD was 4.7 (*p* = 0.002) for AKIN stage 1 AKI patients, and 5.8 (*p* = 0.004) for AKIN stage 2 and 3 AKI patients. Other independent risk factors in the multivariate analysis include diabetes mellitus (HR = 20.607, *p* = 0.003) and lowest haematocrit during bypass (HR = 0.900, *p* = 0.032) (Table [3](#Tab3){ref-type="table"}).Fig. 1Time to end-stage renal disease for the whole cohort Table 3Cox regression analysis of perioperative factors and end-stage renal disease and 5-year all-cause mortalityVariablesEnd-stage renal disease5-year all cause mortalityHR95% C.I.*p*-valueHR95% C.I.*p*-valueDiabetes mellitus20.62.764--153.6530.0031.71.168--2.4380.005Lowest haematocrit during bypass (%)0.90.818--0.9910.0320.90.901--0.9880.013AKIN stage 1 AKI4.71.736--12.6030.0021.71.165--2.5710.007AKIN stage 2--3 AKI5.81.769--18.7320.0042.51.438--4.229\<0.001*AKIN* Acute Kidney Injury Network, *C.I.* Confidence Interval, *HR* Hazard Ratio

All-cause 5-year mortality {#Sec9}
--------------------------

During the follow up period, 95% (*n* = 2538 out of 2666) of patients were alive. The 5-year mortality was 4.8% (*n* = 128 out of 2666).

The mortality amongst the AKI patients was significantly higher than non-AKI patients (7.7 vs 3.6%, *p* \< 0.001). 6.7% of patients with AKI of AKIN stage 1 (*n* = 41 out of 608) died within 5 years of surgery, whereas 10.4 and 14.0% of patients with AKI of AKIN stage 2 (*n* = 14 out of 134) and 3 (*n* = 5 out of 35) died within 5 years of surgery respectively (Table [1](#Tab1){ref-type="table"}).

There was a significant dose-dependent relationship between the severity of AKI and mortality (*p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}). The risk of mortality was 2 and 3 times significantly higher for patients who developed AKI of AKIN stage 1, and stage 2 and 3 respectively (*p* = 0.002, *p* = 0.012) (Table [2](#Tab2){ref-type="table"}). The HR for mortality was 1.7 (*p* = 0.007) for AKIN stage 1 AKI patients, and 2.5 (*p* \< 0.001) for AKIN stage 2 and 3 AKI patients (Table [3](#Tab3){ref-type="table"}).Fig. 2Time to mortality for the whole cohort

Patients who developed ESRD had a 5.4 times (95% C.I. = 2.650--11.059) significant higher risk of developing all-cause 5-year mortality compared to patients who did not develop ESRD (25.0 vs 4.6%, *p* = 0.001).

Relationship between eGFR, AKI and ESRD {#Sec10}
---------------------------------------

There is an inverse relationship between eGFR and ESRD. 88.9% of patients who developed ESRD have eGFR \<60 ml/min/1.73 m^2^ as compared to 5.6% of patients with normal eGFR (≥90 ml/min/1.73 m^2^) and 5.6% with eGFR between 60 and \<90 ml/min/1.73 m^2^ (*p* \< 0.001).

2.3% (18 out of 777) of patients with AKI developed ESRD as compared to 0.3% (6 out of 1889) of patients who did not have AKI but developed ESRD (*p* \< 0.001).

Discussion {#Sec11}
==========

AKI is a serious complication with adverse long-term outcomes. Hitherto, AKI was believed to be self-limiting \[[@CR8]\] but within a 4.4 ± 2.8 years follow-up period, 0.9% patients locally who underwent cardiac surgery developed ESRD.

There is a dose-dependent relationship between AKI and the risk of ESRD. Patients who develoepd ESRD also have a higher 5-fold mortality after cardiac surgery.

Association of AKI and ESRD {#Sec12}
---------------------------

Several epidemiological studies have reported an association between AKI and ESRD \[[@CR16], [@CR17]\]. In a cohort of patients who underwent coronary angiography and developed AKI, the risk of ESRD was more than 4-fold higher in patients with AKIN stage 1 and almost 12-fold higher in patients with AKIN stage 2--3 compared to patients without AKI; and the incidence of ESRD was 0.6% for that study population \[[@CR16]\]. In another cohort of patients who underwent CABG during a 9-year period, 0.4% of the cohort developed ESRD during a mean follow-up of 4.3 ± 2.4 years \[[@CR17]\]. In contrast, during a mean follow-up of 4.4 ± 2.8 years in our population, a total of 24 patients (0.9%) developed ESRD, which is twice as high.

It was previously thought that there is no long-term sequelae of an episode of AKI with expectant recovery of renal function. However, recent evidence from multiple observational studies demonstrated a strong reproducible association between AKI, subsequent CKD and ESRD \[[@CR8], [@CR9], [@CR11], [@CR16]\]. In some cases, this decline in renal function after AKI follows a rapid trajectory with the patient developing accelerated ESRD requiring long-term renal replacement therapy \[[@CR17], [@CR18]\]. We have previously reported that up to 10% of patients who developed AKI in the post-operative period after cardiac surgery have elevated serum creatinine at the point of hospital discharge \[[@CR19]\]. It is clear that some of these patients develop accelerated ESRD within 5 years as shown in this study.

AKI is directly associated with the progression of CKD but it is also postulated that it directly causes CKD \[[@CR20]\]. Our study confirmed a dose-dependent relationship between the increased severity of AKI and increased incidence of ESRD. Other studies have shown that multiple episodes of AKI predict the development of CKD \[[@CR21]\]; and CKD has also been reported in children who had AKI but had no other risk factors such as hypertension, diabetes or cardiovascular disease \[[@CR22]\]. The evidence for primary pathogenic links between AKI and CKD remains to be elucidated, but there is some suggestion that in acute tubular necrosis there is rapid progression to ESRD even in patients without pre-existing CKD \[[@CR20]\].

These findings suggest that an episode of AKI is particularly detrimental in a cohort of cardiac surgical patients who have pre-existing risk factors for CKD. An episode of AKI in itself can cause CKD as well as worsen pre-existing CKD. Animal studies have outlined a number of causal pathways in the progression of renal dysfunction following AKI \[[@CR23]\]. These include maladaptive repair, disordered regeneration or both \[[@CR23]\]. However, relatively little is known about the long-term course of AKI in the setting of cardiac surgery with its attendant ischemic injuries and inflammation and these need to be addressed.

Risk factors of AKI and ESRD {#Sec13}
----------------------------

The patients who developed ESRD after AKI are mainly males with an average age of 57.3 ± 9.4 years. This is relatively young as compared to the age of initiation of dialysis in other populations, such as that in the United States where the average age of patients starting on dialysis is 64.7 ± 14.5 years \[[@CR24]\]. This also reflects the overall younger age of presentation of heart disease in the Asian population, but the early age of presentation of ESRD is particularly alarming given the long-term morbidity and health burden of this chronic disease.

Diabetes mellitus is especially prevalent in the Asian population and diabetics who developed AKI are particularly at risk of developing ESRD. Numerous studies have shown that South Asians have decreased sensitivity to insulin when compared with other ethnic groups which may be related to increased levels of truncal fat and dysfunctional adipose tissue resulting in a blunted response to insulin \[[@CR25]\]. It is well known that diabetes mellitus is the leading cause of ESRD worldwide \[[@CR26]\] and the common consensus is an expected, linear, progressive and time-dependent decline of CKD to ESRD in the diabetic patient \[[@CR17], [@CR18]\]. Perhaps less known is that after an episode of AKI, the trajectory of accelerated ESRD is rapid, and we showed that in our population the rate of decline is as short as 5 years following cardiac surgery. This corroborates with recent publications \[[@CR17], [@CR18]\] and has tremendous implications on ESRD care planning as it affects mainly males of a relatively younger age group compared to their Western counterpart.

Equally important is the modification of risk factors that will retard the risk of AKI and subsequent ESRD. Patients who developed AKI and subsequent ESRD have a lower perioperative haemoglobin and higher rates of transfusion. We have shown previously that pre-operative anaemia increased the risk of AKI by 23% and Asians with a smaller body size are particularly vulnerable to the haemodilution associated with cardiopulmonary bypass and need for subsequent blood transfusion -- a dual insult that exacerbates the hypoxic insult of low haemoglobin and aggravated by initiation of the systemic inflammatory response associated with blood transfusion \[[@CR1]\]. There is debate on the optimal haemoglobin to maintain during cardiopulmonary bypass and it may well differ between diabetic and non-diabetic patients and warrants further investigation.

Pre-operative CKD is a major determinant of post-operative AKI \[[@CR7]\]. The transient loss of renal function (i.e., AKI) in patients with pre-existing CKD can occur via a few pathways, such as the failure of renal autoregulation, abnormal vasodilatation of the renal vasculature, increased susceptibility to side effects of anti-hypertensive agents \[[@CR20]\]. However, it is apparent that even though 29% of our cohort developed AKI, 62.9% of patients with pre-existing renal impairment had non-recovery of acute-on-chronic kidney injury with a steep downhill trajectory and accelerated ESRD \[[@CR17], [@CR18]\].

Continuum of AKI, CKD, ESRD and mortality {#Sec14}
-----------------------------------------

Overall, patients who developed ESRD within the follow-up period have a 5-fold increased risk of mortality compared with those without ESRD.

It is known that patients who survive an episode of AKI are at risk for major adverse cardiovascular events as well as progression to CKD, regardless of whether there is underlying cardiovascular disease \[[@CR16]\]. In this cardiac surgical population with underlying cardiac disease, the added insult of AKI and CKD will further aggravate cardiac disease despite successful revascularization. Studies suggest that "organ crosstalk" may be active long after the initial injury and the acute cardiorenal injury induces a vicious cycle that persists long after the acute event \[[@CR27]\]. Pre-clinical models demonstrate that AKI can result in distant organ effects including cardiac cell apoptosis and cardiac leucocyte infiltration \[[@CR28]--[@CR30]\].

Strengths and limitations {#Sec15}
-------------------------

This is a prospective study of a cohort of cardiac surgical patients with clearly defined data points. The patient population is relatively homogenous with easy access to healthcare. The present study was protocol driven with uniform practice among the various anaesthetists, perfusionists and surgeons ensuring reliability of data.

The Singapore Renal Registry is a well-defined nationwide cohort with extensive baseline information. The data capture for ESRD is estimated to be 95% complete \[[@CR15]\] as the National Registry of Diseases Act in 2009 mandates all physicians to notify, within 3 months from the data of diagnosis, all ESRD cases to the Singapore Renal Registry of the National Registry of Diseases Office \[[@CR31]\].

One of the limitations is that pre-operative renal screening was done using serum creatinine which is the standard of care in Singapore and many parts of the world. Proteinuria is currently not routinely screened in patients undergoing cardiac surgery and this would be part of future prospective studies to enable better renal risk stratification and counselling.

Also, as AKI was previously believed to be self-limiting, patients were not routinely followed up at regular intervals by renal physicians for progression of renal disease.

Conclusions {#Sec16}
===========

We have shown that AKI is associated with the long-term development of ESRD after cardiac surgery. The trajectory of progression from AKI to CKD and ESRD is rapid within 5 years after cardiac surgery. ESRD occurs in a younger age group in our population and leads to significant disease burden and high healthcare costs and mortality. A concerted follow-up assessment by nephrologists after hospital discharge with periodic assessment of renal function and urinary protein-creatinine ratio to assess prognosis and outcome after discharge is advocated for patients who develop AKI after cardiac surgery.
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